Key points for investors:
- Clinical: argenx announced positive Phase III ADAPT OCULUS results in ocular myasthenia gravis (oMG). The study met its primary endpoint (MGII ocular score; p=0.012) with meaningful improvements in ptosis and diplopia. The company plans to file an sBLA for ocular MG. This follows recent positive seronegative MG data; the seronegative PDUFA date is May 10, 2026. Other near-term readouts include empasiprubart in MMN (Q4) and ongoing Phase III programs in myositis and other indications. Next-generation FcRn assets (ARGX-213, ARGX-124) and multiple early programs (ARGX-121, ARGX-118) are advancing.
- Commercial / Market: VYVGART continues strong adoption. ~19,000 patients treated globally at year-end 2025. The prefilled syringe (PFS) launch materially aided uptake; >4,700 prescribers and growing. Company expects to expand addressable MG population by targeting seronegative (~11,000) and ocular (~7,000 eligible) subgroups, moving toward ~60,000 target U.S. MG patients. CIDP launch is earlier stage with a 12,000 core addressable population; company sees early signs of expansion beyond switches from IVIg.
- Financials / Guidance: Q4 product net sales $1.3B; FY 2025 product net sales $4.2B (90% YoY growth). argenx reported operating profit of $367M for Q4 and $1.1B for FY 2025 — the company’s first full-year operating profitability. Gross margin remains ~11% YTD for 2025. Cash and equivalents approx. $4.4B (up >$1B year-over-year). Combined R&D + SG&A was ~$2.7B for 2025 and management expects continued OpEx growth in 2026 (with R&D being the main driver) at a similar percentage rate as prior years. Long-term financial goal: revenue growth to outpace OpEx growth and increasing operating margins over time.
- Access / Reimbursement: Management expects broad access for seronegative and ocular MG and indicated they anticipate a similar net price to existing MG indication (~$225,000 net to argenx). PFS coverage expanded (notably UnitedHealthcare) increasing covered lives to >90%, supporting CIDP and broader uptake.
- Strategy / Org: Leadership transition — Karen Massey named CEO (promoted internally) with Tim Van Hauwermeiren stepping into a new role supporting the company. Management emphasizes Vision 2030: broaden VYVGART use, lead FcRn innovation (next-gen molecules, delivery modalities, combinations), and add at least one new pipeline candidate per year.
- Risks / Timing: Typical Q1 seasonal dynamics (reverifications, weather) could cause near-term variability. Approval-to-payer policy adoption typically takes additional quarters post-approval; management noted ~2 quarters to see broad payer policy updates. As always, forward-looking items (approvals, label expansions, clinical outcomes) are subject to regulatory and clinical risk.
Sign In
Buy ARGX
